Among the most advanced targeting strategies deployed to interfere with TGF-β superfamily signaling in cancer is coupling the small molecule inhibitor galunisertib with anti-PD1 immunotherapy, which resulted in complete regression in murine colon cancer models (54, 122). This evidence concerns the gene TGFB1 and cancer.